Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| COA-M5243 | Mouse | Mouse Complement C3a Protein, His Tag (HPLC verified) |  |
|
|
| COA-H82Q3 | Human | Biotinylated Human Complement C3a Protein, His,Avitag™ |  |
|
|
| COA-H5143 | Human | Human Complement C3a Protein, His Tag |  |
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Pegcetacoplan | APL-2 | Approved | Apellis Pharmaceuticals Inc | Aspaveli, Empaveli | United States | Hemoglobinuria, Paroxysmal | Apellis Pharmaceuticals Inc | 2021-05-14 | Motor Neuron Disease; Rejection of renal transplantation; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Thrombotic Microangiopathies; Glomerulonephritis, Membranous; Lupus Nephritis; Glomerulonephritis, Membranoproliferative; Anemia, Hemolytic, Autoimmune; Geographic Atrophy; Amyotrophic Lateral Sclerosis; Glomerulonephritis; Macular Degeneration | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Efdamrofusp alfa | IBI-302 | Phase 3 Clinical | AP Biosciences Inc | Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration; Plaque psoriasis | Details |
| APL-9 | Phase 2 Clinical | Apellis Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Severe Acute Respiratory Syndrome; Coronavirus Infections | Details | |
| NGM-621 | NGM-621 | Phase 2 Clinical | Ngm Biopharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19); Geographic Atrophy | Details |
| Compstatin 40 | AMY-101 | Phase 2 Clinical | University Of Pennsylvania | Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Gingivitis | Details |
| ADX-097 | ADX-097 | Phase 2 Clinical | Q32 Bio Inc | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glomerulonephritis, IGA; Kidney Diseases; Lupus Nephritis; Nephrosis, Lipoid | Details |
| SGB-9768 | SGB-9768 | Phase 2 Clinical | Suzhou Sanegene Biopharmaceuticals Ltd, Sanegene Bio New Zealand Ltd | Glomerulonephritis, IGA; Kidney Diseases; Glomerulonephritis, Membranoproliferative; Glomerulonephritis | Details |
| KRIYA-825 | KRIYA-825; VV-14295 | Phase 2 Clinical | Kriya Therapeutics Inc | Geographic Atrophy | Details |
| ALXN-2030 | ALXN-2030 | Phase 2 Clinical | Alexion Pharmaceuticals Inc | Rejection of renal transplantation; Rejection of organ transplantation | Details |
| LP-005 | RX-001; LP-005 | Phase 2 Clinical | Longbio Pharma (Suzhou) Co Ltd | Myasthenia Gravis; Peripheral Nervous System Diseases; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Kidney Diseases; Lupus Nephritis; Amyotrophic Lateral Sclerosis | Details |
| ARO-C3 | ARO-C3; ARO-C-3 | Phase 2 Clinical | Arrowhead Pharmaceuticals Inc | Glomerulonephritis, IGA; Glomerulonephritis | Details |
| CG-001 | CG-001 | Phase 1 Clinical | Chengdu Konjin Co Ltd | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Autoimmune Diseases | Details |
| APL-3007 | APL-3007 | Phase 1 Clinical | Apellis Pharmaceuticals Inc | Details | |
| NM3086 | NM3086; NM-3086 | Phase 1 Clinical | NovelMed Therapeutics Inc | Hemoglobinuria, Paroxysmal | Details |
This web search service is supported by Google Inc.
A-Z
